ALNY
ALNYLAM PHARMACEUTICALS, INC.
Nasdaq: ALNY · Cambridge, MA · Healthcare
$297.69+5.53 (+1.89%)Closed
Market Cap$39.39B
Cash$1.66Bmost recent
Runway42 mo$118.3M Q burn
P/E (TTM)127.7EPS $2.33
52-Wk Range$284.84 – $491.22
Avg Volume1.2M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$297.69+94.0%
Pipeline
Drug candidates sponsored by ALNYLAM PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Revusiran (ALN-TTRSC) | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)+6 more | Completed | 2017-03-30past | 2 | |
| Phase 3 | patisiran (ALN-TTR02) | TTR-mediated Amyloidosis+6 more | Completed | 2017-08past | 3 | |
| Phase 3 | Givosiran | Acute Hepatic Porphyria+8 more | Completed | 2021-11-05past | 4 | |
| Phase 3 | Patisiran | Amyloidosis, Familial+8 more | Completed | 2022-11-23past | 6 | |
| Phase 3 | Lumasiran | Primary Hyperoxaluria+8 more | Completed | 2023-02-07past | 6 | |
| Phase 3 | Placebo | Primary Hyperoxaluria Type 1 (PH1)+6 more | Recruiting | 2027-08-09 | 5 | |
| Phase 3 | Nucresiran | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy+2 more | Recruiting | 2027-12-27 | 2 | |
| Phase 3 | Vutrisiran | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Active, not recruiting | 2028-03-31 | 2 | |
| Phase 3 | Zilebesiran | High Risk Cardiovascular Disease+3 more | Recruiting | 2030-09-30 | 3 | |
| Phase 2 | ALN-RSV01 | Respiratory Syncytial Virus Infections | Completed | 2012-04past | 3 | |
| Phase 2 | ALN-TTRSC (revusiran) for subcutaneous administration | TTR-mediated Amyloidosis | Completed | 2014-10past | 1 | |
| Phase 1 | ALN-CC5 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2016-04past | 1 | |
| Phase 2 | ALN-TTR02 (patisiran) administered by intravenous (IV) infusion | TTR-mediated Amyloidosis | Completed | 2016-07past | 1 | |
| Phase 2 | Revusiran | Transthyretin (TTR)-Mediated Amyloidosis+3 more | Completed | 2017-02-06past | 1 | |
| Phase 2 | Cemdisiran | Atypical Hemolytic Uremic Syndrome | Withdrawn | 2018-09-12past | 1 | |
| Phase 1 | ALN-AAT02 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | Terminated | 2020-06-25past | 1 | |
| Phase 1 | ALN-XDH | Gout | Terminated | 2023-01-25past | 1 | |
| Phase 2 | Indapamide | Hypertension | Completed | 2023-12-11past | 1 | |
| Phase 1 | ALN-KHK | Type 2 Diabetes Mellitus (T2DM) | Terminated | 2025-04-03past | 1 | |
| Phase 1 | ALN-2232 | Obesity | Recruiting | 2027-04-27 | 1 | |
| Phase 2 | ALN-4324 | Type 2 Diabetes Mellitus (T2DM)+1 more | Recruiting | 2027-05-28 | 2 | |
| Phase 2 | ALN-6400 | Von Willebrand Disease (VWD)+2 more | Recruiting | 2027-06-30 | 2 | |
| Phase 2 | ALN-AGT01 RVR | Hypertension+1 more | Recruiting | 2028-04-01 | 2 | |
| Phase 2 | Mivelsiran | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Not yet recruiting | 2030-05-18 | 1 | |
| Phase 1 | ALN-TTR01 | Transthyretin Mediated Amyloidosis (ATTR) | Completed | 2012-01past | 1 | |
| Phase 1 | ALN-PCS02 | Elevated LDL-Cholesterol (LDL-C) | Completed | 2012-03past | 1 | |
| Phase 1 | ALN-TTR02 | TTR-mediated Amyloidosis | Completed | 2012-06past | 1 | |
| Phase 1 | ALN-VSP02 | Solid Tumors | Completed | 2012-08past | 2 | |
| Phase 1 | ALN-TTRSC (revusiran) | TTR-mediated Amyloidosis | Completed | 2015-04past | 1 | |
| Phase 1 | ALN-PCSSC | Hypercholesterolemia | Completed | 2015-05past | 1 | |
| Phase 1 | givosiran (ALN-AS1) | Acute Intermittent Porphyria | Completed | 2017-09-06past | 1 | |
| Phase 1 | ALN-HBV | Hepatitis B+4 more | Terminated | 2017-10past | 1 | |
| Phase 1 | ALN-AAT | Antitrypsin Deficiency Liver Disease | Terminated | 2018-01-03past | 1 | |
| Phase 1 | ALN-TTRSC02 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | Completed | 2018-01-12past | 1 | |
| Phase 1 | ALN-AGT01 | Hypertension | Completed | 2022-04-20past | 1 | |
| Phase 1 | ALN-HSD | Nonalcoholic Steatohepatitis+1 more | Terminated | 2023-01-06past | 1 | |
| Phase 1 | ALN-TTRSC04 | Transthyretin-Mediated Amyloidosis | Completed | 2025-09-30past | 1 | |
| Phase 1 | ALN-4285 | Healthy Volunteers | Recruiting | 2026-12-29 | 1 | |
| Phase 1 | ALN-4915 | Healthy Volunteers | Recruiting | 2027-07-31 | 1 | |
| Phase 1 | ALN-BCAT | Advanced Hepatocellular Carcinoma+1 more | Recruiting | 2027-09-30 | 1 | |
| Phase 1 | ALN-6222 | Obesity | Not yet recruiting | 2027-12-14 | 1 | |
| Phase 1 | ALN-HTT02 | Huntington's Disease | Recruiting | 2028-07-05 | 1 | |
| Phase 1 | ALN-APP | Early-Onset Alzheimer Disease | Recruiting | 2029-04-20 | 1 | |
| Phase 1 | ALN-5288 | Alzheimer's Disease | Recruiting | 2030-03-06 | 1 | |
| N/A | Unnamed | Familial Amyloidotic Cardiomyopathy (FAC) | Completed | 2016-01past | 1 | |
| N/A | Unnamed | Acute Hepatic Porphyria+6 more | Terminated | 2019-01-15past | 1 | |
| N/A | Unnamed | Amyloidosis+1 more | Terminated | 2020-05-18past | 1 | |
| N/A | Unnamed | Acute Hepatic Porphyria | Completed | 2021-04-26past | 1 | |
| N/A | Unnamed | Acute Hepatic Porphyria | Recruiting | 2027-04-01 | 1 | |
| N/A | Unnamed | Hereditary Amyloidosis, Transthyretin-Related+1 more | Active, not recruiting | 2027-12-01 | 1 | |
| N/A | Unnamed | Primary Hyperoxaluria Type 1 | Active, not recruiting | 2028-09-01 | 1 | |
| N/A | Unnamed | Hereditary Transthyretin-mediated (hATTR) Amyloidosis+1 more | Recruiting | 2030-10-12 | 1 | |
| N/A | Unnamed | Transthyretin Amyloidosis With Cardiomyopathy | Recruiting | 2030-10-23 | 1 | |
| N/A | Unnamed | Transthyretin-Mediated Amyloidosis+1 more | Recruiting | 2033-12-31 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for ALNY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.